BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37446326)

  • 1. MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells.
    Pratelli G; Carlisi D; Di Liberto D; Notaro A; Giuliano M; D'Anneo A; Lauricella M; Emanuele S; Calvaruso G; De Blasio A
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
    De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
    J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
    Shome R; Ghosh SS
    ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
    Wang K; Zou P; Zhu X; Zhang T
    Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
    Kashyap A; Umar SM; Dev J R A; Prasad CP
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
    Guo Y; Fan Y; Pei X
    Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR is a pivotal player of the E2/ERβ - mediated functional properties, aggressiveness, and stemness in triple-negative breast cancer cells.
    Kyriakopoulou K; Kefali E; Piperigkou Z; Riethmüller C; Greve B; Franchi M; Götte M; Karamanos NK
    FEBS J; 2022 Mar; 289(6):1552-1574. PubMed ID: 34665934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway.
    Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W
    Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyanidin-3-glucoside induces mesenchymal to epithelial transition via activating Sirt1 expression in triple negative breast cancer cells.
    Liang L; Liu X; He J; Shao Y; Liu J; Wang Z; Xia L; Han T; Wu P
    Biochimie; 2019 Jul; 162():107-115. PubMed ID: 30876970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
    Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
    Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin β3.
    Liu S; Dong Y; Wang Y; Hu P; Wang J; Wang RY
    Biomed J; 2021 Dec; 44(6 Suppl 1):S84-S92. PubMed ID: 35652598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
    Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
    BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
    Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
    Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.
    Das K; Paul S; Singh A; Ghosh A; Roy A; Ansari SA; Prasad R; Mukherjee A; Sen P
    J Biol Chem; 2019 Sep; 294(37):13681-13696. PubMed ID: 31341019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
    D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
    Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
    Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
    J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
    Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
    Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.